3rd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma

The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. Building upon this success, the Third IMS Genomics Meeting will be a public meeting led by global myeloma KOL.
More details will be available soon.